The Appliance of Life Science Looks Exciting for this On-the-Nose Medical Explorer. September 11, 2019 – Posted in: Tiziana Life Sciences (TILS)

by Malcolm Stacey Hello, Share Troopers. Previously, I’ve written on the huge potential of life science companies which explore antibodies and antibody substitutes in the fight against serious conditions like cancer. Allow me to put another such firm before you. Tiziana Life Sciences plc (TILS) is biotechnology outfit which uses antibodies to find new treatments for inflammatory diseases and cancers. The company has just announced good news which sent the share price alight this week.…

Alan Green discusses Cadence Minerals #KDNC, Tiziana Life #TILS, JD Sports #JD & Itaconix #ITX on the Vox Markets podcast September 10, 2019 – Posted in: Blog, Tiziana Life Sciences (TILS)

Alan Green discusses Cadence Minerals #KDNC Amapa project, Tiziana Life Sciences (AIM: #TILS, Nasdaq: #TLSA), JD Sports #JD and Itaconix #ITX on the Vox Markets podcast. The interview is 14 minutes 28 seconds in.

Tiziana Life Sciences #TILS Reports Phase 1 Clinical Data Demonstrating Nasal Treatment with Foralumab was Well-tolerated and Produced Positive Trend in Biomarkers – Posted in: Tiziana Life Sciences (TILS)

THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Tiziana Life Sciences plc Tiziana Reports Phase 1 Clinical Data Demonstrating Nasal Treatment with Foralumab was Well-tolerated and Produced Positive Trend in Biomarkers of Immunomodulation and Anti-inflammation in Healthy Volunteers New…

Tiziana Life Sci – Positive Phase 2a Clinical Data September 4, 2019 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences Reports Positive Phase 2a Clinical Data Exhibiting Positive Clinical Activity with Milciclib Monotherapy in Advanced Sorafenib-refractory or -intolerant Patients with Unresectable or Metastatic Hepatocellular Carcinoma New York/London, 4 September 2019 – Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today announced additional positive Phase 2a clinical data exhibiting impressive clinical activity of Milciclib monotherapy in…

Tiziana Life Sciences #TILS – Proposed US Public Offering August 6, 2019 – Posted in: Tiziana Life Sciences (TILS)

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Tiziana Announces Publication of Registration Statement on Form F-1 and Proposed U.S. Public Offering of ADSs New York and London, August 6, 2019 – Tiziana Life Sciences…

Tiziana Life Sciences (TILS) Tiziana Reports Phase 2a Clinical Data with Milciclib Monotherapy in patients with advanced Hepatocellular Carcinoma liver cancer July 21, 2019 – Posted in: Tiziana Life Sciences (TILS)

Milciclib was well tolerated and no drug related deaths were reported 28 out 31 treated patients were evaluable, with 14 patients completing the 6-month study duration 9 patients continued treatment under compassionate use, of which 5 are currently continuing with treatment New York/London, 22 July 2019 – Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today announced…

Alan Green discusses Tiziana Life #TILS, BigDish #DISH and Tertiary Minerals #TYM on the Vox Markets podcast July 17, 2019 – Posted in: BigDish (DISH), Tiziana Life Sciences (TILS)

Alan Green discusses Tiziana Life Sciences (AIM: TILS, Nasdaq: TLSA), BigDish (AIM: DISH) and Tertiary Minerals (AIM: TYM) on the Vox Markets podcast. The interview is 7 minutes 50 seconds in.

Small Cap Stock Picks: Alan Green, Brand Communications CEO discusses RAI, TILS, KDNC and DISH on IG UK with Jeremy Naylor July 8, 2019 – Posted in: BigDish (DISH), Tiziana Life Sciences (TILS)

Small Cap Stock Picks: Alan Green, Brand CEO discusses RA International Group (RAI), Tiziana Life Sciences (TILS), Cadence Minerals (KDNC) and BigDish (DISH) on IG UK with Jeremy Naylor.

Tiziana Life Sci PLC (TILS) Teplizumab Article July 4, 2019 – Posted in: Tiziana Life Sciences (TILS)

Independent Third Party Article in New England Journal of Medicine reports on Intravenous Treatment with a Humanized Anti-CD3 mAb showing delays in progression of Type 1 Diabetes; Findings may have the potential to expand therapeutic benefits of Tiziana’s Foralumab, the only known fully human anti-CD3 mAb Independent third party Phase 2 results show Teplizumab, a mouse derived humanized anti-CD3 monoclonal antibody (mAb) significantly slowed progression of Type 1 diabetes in high risk population Tiziana Life…

Tiziana Life Sci PLC (TILS) Change of Adviser – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, announces the appointment of Shore Capital Stockbrokers Limited as Broker, with immediate effect. This follows the acquisition of Stockdale Securities Limited by Shore Capital Markets Limited. For further enquiries: Tiziana Life Sciences plc +44 (0)20 7493 2853 Gabriele Cerrone, Chairman and founder …